| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 25 | 2026 | 410 | 3.900 |
Why?
|
| Medical Oncology | 10 | 2026 | 423 | 2.740 |
Why?
|
| Neoplasms | 19 | 2026 | 3348 | 2.160 |
Why?
|
| Electronic Health Records | 7 | 2026 | 450 | 1.800 |
Why?
|
| Pediatrics | 6 | 2026 | 421 | 1.390 |
Why?
|
| Information Dissemination | 8 | 2026 | 133 | 1.360 |
Why?
|
| Natural Language Processing | 2 | 2023 | 44 | 1.310 |
Why?
|
| Child | 37 | 2026 | 7730 | 1.270 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1126 | 1.090 |
Why?
|
| Medical Informatics | 4 | 2021 | 50 | 1.020 |
Why?
|
| Databases, Factual | 8 | 2025 | 1097 | 0.960 |
Why?
|
| Trees | 1 | 2025 | 48 | 0.870 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2015 | 403 | 0.780 |
Why?
|
| Software | 4 | 2019 | 693 | 0.750 |
Why?
|
| Pathology, Molecular | 2 | 2019 | 36 | 0.720 |
Why?
|
| Leukemia | 1 | 2023 | 309 | 0.660 |
Why?
|
| Humans | 77 | 2026 | 98223 | 0.660 |
Why?
|
| Biomedical Research | 4 | 2025 | 471 | 0.650 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 533 | 0.640 |
Why?
|
| Research Report | 2 | 2021 | 43 | 0.630 |
Why?
|
| Asthma | 2 | 2025 | 1082 | 0.600 |
Why?
|
| Heuristics | 1 | 2019 | 15 | 0.600 |
Why?
|
| Rhabdomyosarcoma | 3 | 2025 | 44 | 0.590 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 183 | 0.590 |
Why?
|
| Child, Preschool | 17 | 2026 | 4026 | 0.560 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2025 | 126 | 0.550 |
Why?
|
| Infant | 19 | 2026 | 3348 | 0.540 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1566 | 0.500 |
Why?
|
| Hospital Units | 1 | 2016 | 29 | 0.490 |
Why?
|
| Pharmacogenetics | 4 | 2025 | 473 | 0.480 |
Why?
|
| Emergencies | 1 | 2016 | 122 | 0.470 |
Why?
|
| Management Information Systems | 1 | 2016 | 3 | 0.470 |
Why?
|
| Adolescent | 19 | 2026 | 10127 | 0.460 |
Why?
|
| Patient Transfer | 1 | 2016 | 112 | 0.450 |
Why?
|
| Pressure Ulcer | 1 | 2016 | 45 | 0.450 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1770 | 0.440 |
Why?
|
| Telemedicine | 1 | 2018 | 252 | 0.440 |
Why?
|
| Polysaccharides | 1 | 2015 | 99 | 0.420 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 643 | 0.410 |
Why?
|
| Patient Care Team | 1 | 2016 | 318 | 0.400 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 50 | 0.390 |
Why?
|
| Heart Arrest | 1 | 2016 | 315 | 0.380 |
Why?
|
| Critical Care | 1 | 2016 | 462 | 0.380 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 3 | 2001 | 11 | 0.360 |
Why?
|
| Lysine | 2 | 2011 | 170 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 184 | 0.360 |
Why?
|
| Algorithms | 4 | 2019 | 2001 | 0.360 |
Why?
|
| Proteomics | 5 | 2016 | 279 | 0.350 |
Why?
|
| Oxidoreductases | 3 | 2001 | 112 | 0.350 |
Why?
|
| Genomics | 5 | 2026 | 902 | 0.330 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 63 | 0.330 |
Why?
|
| Loss of Heterozygosity | 2 | 2014 | 85 | 0.320 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2021 | 20 | 0.320 |
Why?
|
| Patient Selection | 2 | 2024 | 721 | 0.300 |
Why?
|
| Registries | 3 | 2026 | 1127 | 0.300 |
Why?
|
| Young Adult | 13 | 2026 | 7556 | 0.290 |
Why?
|
| Isotope Labeling | 1 | 2009 | 54 | 0.290 |
Why?
|
| Databases, Protein | 1 | 2009 | 52 | 0.290 |
Why?
|
| Computational Biology | 2 | 2015 | 615 | 0.280 |
Why?
|
| Machine Learning | 3 | 2022 | 408 | 0.280 |
Why?
|
| Precision Medicine | 5 | 2025 | 501 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2570 | 0.260 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 477 | 0.260 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2017 | 41 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2026 | 2569 | 0.260 |
Why?
|
| Age Factors | 4 | 2021 | 1972 | 0.260 |
Why?
|
| Male | 21 | 2026 | 47195 | 0.250 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 233 | 0.250 |
Why?
|
| Cohort Studies | 9 | 2021 | 3217 | 0.250 |
Why?
|
| Female | 22 | 2026 | 51685 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 571 | 0.240 |
Why?
|
| Congenital Abnormalities | 1 | 2026 | 69 | 0.230 |
Why?
|
| Biological Specimen Banks | 1 | 2026 | 82 | 0.230 |
Why?
|
| Rare Diseases | 1 | 2026 | 74 | 0.230 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2026 | 52 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2789 | 0.220 |
Why?
|
| Patient Portals | 1 | 2025 | 36 | 0.210 |
Why?
|
| Acyl Coenzyme A | 2 | 2001 | 17 | 0.210 |
Why?
|
| Gene Amplification | 2 | 2017 | 142 | 0.210 |
Why?
|
| Sarcoma | 2 | 2025 | 222 | 0.210 |
Why?
|
| Data Mining | 1 | 2024 | 45 | 0.210 |
Why?
|
| Hematology | 1 | 2024 | 37 | 0.200 |
Why?
|
| Proteins | 1 | 2009 | 803 | 0.200 |
Why?
|
| Prognosis | 9 | 2024 | 4126 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 244 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2025 | 228 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2024 | 144 | 0.190 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2000 | 11 | 0.190 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 66 | 0.190 |
Why?
|
| Eligibility Determination | 1 | 2023 | 41 | 0.190 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 2020 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 2 | 2025 | 119 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 38 | 0.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 7 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 666 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 1858 | 0.180 |
Why?
|
| Disease Progression | 2 | 2025 | 1612 | 0.180 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 102 | 0.180 |
Why?
|
| Chicago | 2 | 2025 | 1519 | 0.180 |
Why?
|
| Mutation | 4 | 2015 | 4408 | 0.180 |
Why?
|
| Data Collection | 2 | 2023 | 375 | 0.170 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 126 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2894 | 0.170 |
Why?
|
| User-Computer Interface | 2 | 2019 | 194 | 0.170 |
Why?
|
| Arginine | 1 | 2001 | 143 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 121 | 0.170 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 2085 | 0.160 |
Why?
|
| Adult | 12 | 2025 | 29548 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 372 | 0.160 |
Why?
|
| Risk Factors | 9 | 2026 | 6269 | 0.160 |
Why?
|
| Substrate Specificity | 1 | 2001 | 374 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2026 | 4815 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2026 | 649 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 24 | 0.150 |
Why?
|
| Survivorship | 1 | 2020 | 27 | 0.150 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 38 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 700 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 132 | 0.150 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 10 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 86 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 752 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 2660 | 0.140 |
Why?
|
| Biomedical Technology | 1 | 2018 | 27 | 0.140 |
Why?
|
| Research | 1 | 2020 | 257 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1539 | 0.140 |
Why?
|
| Infant, Newborn | 5 | 2026 | 2544 | 0.140 |
Why?
|
| Smartphone | 1 | 2018 | 53 | 0.140 |
Why?
|
| Survivors | 2 | 2016 | 211 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2018 | 44 | 0.130 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 45 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 813 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 29 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 214 | 0.130 |
Why?
|
| Coronary Care Units | 1 | 2016 | 5 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2021 | 1528 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 618 | 0.120 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 156 | 0.120 |
Why?
|
| Caspase 10 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Melphalan | 1 | 2016 | 98 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 69 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 79 | 0.120 |
Why?
|
| Hydrazines | 1 | 2015 | 36 | 0.120 |
Why?
|
| Mitochondria | 1 | 2000 | 648 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 160 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 136 | 0.110 |
Why?
|
| Physician's Role | 1 | 2017 | 181 | 0.110 |
Why?
|
| Carbohydrate Sequence | 1 | 2015 | 18 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 23 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 2894 | 0.110 |
Why?
|
| Proteome | 1 | 2016 | 164 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 118 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 195 | 0.110 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 7 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2021 | 826 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 726 | 0.110 |
Why?
|
| Glycosylation | 1 | 2015 | 141 | 0.110 |
Why?
|
| Exome | 1 | 2015 | 147 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 331 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 246 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2015 | 89 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2015 | 205 | 0.100 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 24 | 0.100 |
Why?
|
| Skull | 1 | 2016 | 279 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2019 | 484 | 0.100 |
Why?
|
| Protein Conformation | 2 | 2011 | 927 | 0.100 |
Why?
|
| DNA Repair | 2 | 2016 | 363 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2022 | 2598 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 141 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 119 | 0.100 |
Why?
|
| Critical Illness | 1 | 2016 | 361 | 0.100 |
Why?
|
| Neurocalcin | 1 | 2013 | 2 | 0.100 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2013 | 30 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2016 | 381 | 0.100 |
Why?
|
| Inpatients | 1 | 2016 | 367 | 0.100 |
Why?
|
| Citric Acid | 1 | 2013 | 47 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1142 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 160 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 200 | 0.100 |
Why?
|
| Research Design | 2 | 2026 | 650 | 0.090 |
Why?
|
| Middle Aged | 5 | 2025 | 29494 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 914 | 0.090 |
Why?
|
| Isovaleryl-CoA Dehydrogenase | 3 | 2001 | 3 | 0.090 |
Why?
|
| Heparin | 1 | 2013 | 182 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 399 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2014 | 325 | 0.090 |
Why?
|
| Enzyme Stability | 3 | 2001 | 48 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 977 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1395 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 402 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 43 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2014 | 309 | 0.090 |
Why?
|
| Acetylation | 1 | 2011 | 150 | 0.090 |
Why?
|
| Ubiquitin | 1 | 2011 | 95 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 479 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7409 | 0.080 |
Why?
|
| Gene Expression | 1 | 2015 | 1321 | 0.080 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 340 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 1194 | 0.080 |
Why?
|
| Methylation | 1 | 2011 | 294 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 5573 | 0.080 |
Why?
|
| Survival Rate | 3 | 2024 | 2050 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1751 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 850 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2014 | 560 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 731 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2011 | 519 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 828 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 843 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 568 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1752 | 0.070 |
Why?
|
| Aged | 4 | 2025 | 21824 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 82 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 106 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 65 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2011 | 1145 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2009 | 51 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 2482 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 107 | 0.070 |
Why?
|
| Isoantibodies | 1 | 2010 | 135 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2010 | 286 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 188 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 129 | 0.070 |
Why?
|
| Ecosystem | 2 | 2023 | 424 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 267 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2009 | 153 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2379 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 352 | 0.070 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 158 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 1090 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2009 | 480 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 154 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2001 | 1392 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1063 | 0.060 |
Why?
|
| United States | 3 | 2026 | 8252 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2026 | 195 | 0.060 |
Why?
|
| North America | 1 | 2026 | 210 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2016 | 317 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1717 | 0.060 |
Why?
|
| Gene-Environment Interaction | 1 | 2026 | 125 | 0.050 |
Why?
|
| Mice | 3 | 2016 | 12718 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2025 | 9750 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1805 | 0.050 |
Why?
|
| Genotype | 1 | 2009 | 1891 | 0.050 |
Why?
|
| Health Information Interoperability | 1 | 2024 | 13 | 0.050 |
Why?
|
| Protein Binding | 2 | 2013 | 1557 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 75 | 0.050 |
Why?
|
| Patient Participation | 1 | 2025 | 250 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 4041 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 994 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2026 | 599 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2022 | 140 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 74 | 0.040 |
Why?
|
| Africa | 1 | 2022 | 113 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 11031 | 0.040 |
Why?
|
| Energy Transfer | 1 | 2001 | 25 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 83 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1786 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 334 | 0.040 |
Why?
|
| Research Subjects | 1 | 2021 | 80 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hemiterpenes | 1 | 2000 | 6 | 0.040 |
Why?
|
| Pentanoic Acids | 1 | 2000 | 7 | 0.040 |
Why?
|
| Leucine | 1 | 2000 | 57 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 28950 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 420 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 118 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 324 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 403 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 402 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 921 | 0.040 |
Why?
|
| Warfarin | 1 | 2019 | 109 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 1159 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 425 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 44 | 0.030 |
Why?
|
| Durapatite | 1 | 2016 | 36 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2003 | 0.030 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 6 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 90 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2015 | 38 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 108 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 52 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 165 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 716 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 913 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 81 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 310 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 83 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 56 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1028 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 57 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 137 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2014 | 61 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 98 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 679 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 16 | 0.030 |
Why?
|
| Computer Security | 1 | 2014 | 18 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 368 | 0.030 |
Why?
|
| Information Systems | 1 | 2014 | 29 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 285 | 0.030 |
Why?
|
| Confidentiality | 1 | 2014 | 77 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 198 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 557 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 177 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 2020 | 0.020 |
Why?
|
| SEER Program | 1 | 2014 | 247 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 318 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 54 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 2002 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 383 | 0.020 |
Why?
|
| Internet | 1 | 2015 | 358 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 276 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 293 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 520 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 552 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 718 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 615 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1784 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Laryngeal Edema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2010 | 22 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 978 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2010 | 43 | 0.020 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 22 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 670 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 154 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 826 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 79 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 295 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1201 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2575 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1647 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 836 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1569 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 2010 | 341 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 3279 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1998 | 29 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1998 | 102 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 380 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1998 | 530 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1998 | 551 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 1477 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1255 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 571 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 766 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2856 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 4073 | 0.010 |
Why?
|